Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Dx Firm Cernostics Raises $1.4M

NEW YORK (GenomeWeb News) – Cancer diagnostics and prognostics firm Cernostics recently announced it raised $1.4 million in a Series B financing round.

The funds will be used to further develop and commercialize the Pittsburgh-based company's lead product called TissueCypher:Barrett's. Its technology, Cernostics said, quantifies whole slide digital images, providing more information and accuracy than traditional subjective tissue diagnostics and will help eliminate uncertainty around treatment for Barrett's esophagus.

The TissueCypher technology is a digital platform "for multi-channel fluorescence whole slide imaging, and includes image reading, image segmentation, biomarker expression, and tissue structure evaluation," the company said on its website.

Existing investors participating in the Series B round included Novitas Capital, Geisinger Health System, and the Pittsburgh Life Sciences Greenhouse. Cernostics said it has raised more than $6 million since its founding.

Cernostics CEO Mike Hoerres said in a statement that the company has completed early clinical validation for TissueCypher:Barrett's, and the recent funding "enables us to take our next steps towards commercialization, both for our lead Barrett's esophagus product, and the other products in our pipeline."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.